Is palmitoyl tetrapeptide-7 FDA-approved, and what does the research show?

What is palmitoyl tetrapeptide-7?

Palmitoyl tetrapeptide-7 is a synthetic peptide, a chain of four amino acids made in a laboratory ¹. The four are glycine, glutamine, proline and arginine, written GQPR, and a 16-carbon fatty acid, palmitic acid, is attached at one end ¹,⁶. The fatty tail is meant to carry a water-loving peptide into the skin's oily outer layer ⁶. The peptide part is "a natural fragment of the IgG immunoglobulins," the antibody proteins of the immune system, in the words of the Cosmetic Ingredient Review, an industry-funded expert panel ¹,⁹.

In cosmetics it is listed as a skin conditioning agent ¹. It is best known as one of the two peptides in Matrixyl 3000, a blend with palmitoyl tripeptide-1 ¹,⁶. A 2022 review called it the most widely used peptide in anti-aging products in 2018 ⁶. Its shorthand is Pal-GQPR ¹.

Is palmitoyl tetrapeptide-7 FDA-approved?

No, because FDA does not approve cosmetic ingredients before sale, apart from color additives ³. In FDA's own words on its cosmetics-authority page, current as of November 18, 2025, "cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives" ³. Companies that make or sell a cosmetic "have a legal responsibility to ensure the safety of their products" ³. Nor does the law oblige them to send FDA their safety information ³. It is not approved as a drug either: Drugs@FDA lists no approved palmitoyl tetrapeptide-7 product as of November 9, 2026 ⁴.

FDA sorts a product into cosmetic or drug by its intended use, read from, among other things, the claims on its label and in its advertising ¹⁰. Anything "intended to affect the structure or any function of the body" counts as a drug under the law ¹⁰.

FDA's page on anti-aging products draws the line in plain words. A product "intended to make lines and wrinkles less noticeable, simply by moisturizing the skin" is a cosmetic ¹¹. A product meant "to remove wrinkles or increase the skin's production of collagen" is, in FDA's words, "a drug or a medical device" ¹¹. The same page says FDA "is concerned about drug claims made for products marketed as cosmetics, such as skin care products with anti-wrinkle or anti-aging claims" ¹¹.

The Modernization of Cosmetics Regulation Act of 2022, known as MoCRA, widened FDA's powers over cosmetics ¹². FDA can now order a recall of an adulterated or misbranded cosmetic likely to cause serious harm "if the responsible person refuses to do so voluntarily" ¹². Companies must report serious adverse events to FDA within 15 business days ¹².

The Cosmetic Ingredient Review is an expert panel funded by the cosmetics industry's trade association; the panel says its review process is independent of the industry ⁹. It issued its final safety report on this peptide on June 30, 2014, and a panel's review is not an FDA approval ¹.

See the FDA status of every peptide, updated weekly.

How does palmitoyl tetrapeptide-7 work?

The proposed mechanism is that of a signal peptide ¹,⁵. The panel's report describes such peptides as "modeled on repair-signaling sequences" of the skin's supporting matrix, and notes that they "have been claimed" to rejuvenate skin ¹.

Shown in cells: the 2023 serum paper describes the peptide as reducing interleukin-6, an inflammatory messenger, in keratinocytes, the skin's surface cells ⁷. The same paper says it damps the skin's inflammatory response to ultraviolet B ⁷. A 2021 review repeats those findings and adds that the peptide stimulates production of laminins and collagen VII, proteins of the junction between the outer and inner skin layers ². The review's source for all of it is a study by scientists of the blend's maker, and the review does not say in what system each finding was made ²,¹³.

Shown in cells: in the 2024 eye-cream study, the cream's four-ingredient active complex increased fibroblast growth and collagen and elastin output in cultured human skin cells ⁵. That test was of the complex, not the peptide alone ⁵.

Nobody has shown how much of it gets past the skin's surface. The 2022 review found "no published studies on the permeability of this palmitoyl peptide" ⁶. A 2026 study then applied a serum containing the blend to the skin of three healthy women ⁸. Pal-GQPR turned up in all the layers of the stratum corneum, the skin's dead outer sheet, apparently sitting between its cells ⁸. None of these sources shows what the peptide does in the living layers beneath.

What does the research show?

No published trial of palmitoyl tetrapeptide-7 on its own was found in a PubMed search on November 10, 2026. Every human study opened tests a blend or a multi-ingredient product ¹,⁵,².

Studied in people: a 2024 split-face trial in China enrolled 37 healthy women aged 20 to 55 with wrinkles around the eyes ⁵. Each applied an eye cream containing palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, N-acetylneuraminic acid and a yeast-rice ferment to one side of the eye area twice daily for 12 weeks ⁵. The other side was left untreated for comparison ⁵. The paper calls itself randomized and double-blind, yet the authors also write that the study "did not include a control or placebo group" ⁵.

At 12 weeks the treated side measured 28.12 percent higher skin hydration and 54.99 percent higher collagen density by ultrasound than the control side ⁵. The abstract reports 18.81 percent higher elasticity ⁵. The company that supplied the cream employs four of the authors ⁵.

Studied in people: the 2023 study in this page's reading list tested a multi-peptide eye serum, not this ingredient alone ⁷. The serum carried 4 percent Matrixyl 3000, 10 percent acetyl hexapeptide-8 and 2 percent of a third blend that also contains palmitoyl tetrapeptide-7 ⁷. Of 34 women aged 20 to 45 who enrolled, 32 completed 28 days of twice-daily use, and there was no control group ⁷.

Against baseline, wrinkle number fell 33.29 percent and wrinkle volume 12.69 percent by image analysis ⁷. Hydration and elasticity did not change significantly in the paper's table, although its abstract says they rose ⁷. Two authors work for Dingmageili Biotechnology, which the PubMed record lists as the funder, and the serum came from another company ⁷.

In the Cosmetic Ingredient Review's record, a half-face study reported in the maker's own synopsis compared Matrixyl 3000 at 3 percent in a cream with a placebo cream ¹. It enrolled 24 volunteers with a mean age of 56.1 years for two months ¹. The blend side showed a statistically significant decrease in deep wrinkles and roughness and an increase in elasticity against day 0 ¹. The placebo side showed no significant change, and the report gives no comparison of the two sides ¹.

A 2015 study by the maker's scientists compared the blend with placebo by ultrasound and confocal microscopy in a number of people the abstract does not give ¹³. It found the matrix structure improved and called its imaging method preliminary ¹³.

The 2021 review's verdict on the seven cosmetic peptides it reviewed, this one among them, is that "the available data is mostly found in patents and supplier brochures, and not in randomized placebo-controlled studies" ². Long-term use, use on broken or diseased skin, and the ingredient by itself have not been studied in any source opened.

What are the side effects?

In the Cosmetic Ingredient Review's record, Rigin is a trade mixture containing 500 parts per million of the peptide ¹. It went through a repeat-insult patch test in 52 healthy men and women aged 18 to 79 ¹. That test applies the product to the same patch of skin again and again to look for irritation and allergy ¹. The result "did not indicate a potential for dermal irritation or allergic contact sensitization" ¹.

The same mixture was "slightly irritating" in a hen's-egg membrane test, a laboratory stand-in for the eye ¹. Its Ames test for genetic damage in bacteria was negative ¹.

The panel found no data on carcinogenicity or reproductive toxicity in the published literature ¹. The industry survey of use concentrations did not include this peptide ¹. In June 2014 it concluded that the ingredient is "safe in the present practices of use and concentration in cosmetics" ¹. It limited that conclusion to the GQPR sequence and rested it on typical use below 10 parts per million and negative safety tests ¹.

In the 2024 trial, dermatologists observed no adverse reactions over 12 weeks in 37 women ⁵. They looked for papules, which are small bumps, erythema, which is redness, scabbing and desquamation, which is peeling ⁵. The 2023 serum study reported "no adverse reactions related to product use" in 32 women over 28 days ⁷. FDA has written nothing about this ingredient in any page opened.

In sport

Palmitoyl tetrapeptide-7 is not named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency ¹⁴.

What JumpstartMD offers

JumpstartMD does not prescribe palmitoyl tetrapeptide-7. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.